Albany, New York, May 9, 2018: The microbiome therapeutics landscape is one that is brimming with opportunity. During the period 2018-2025, the microbiome therapeutics market is likely to witness a CAGR of over 62%, which is indicative of the emerging opportunities in this landscape. A latest report titled “Global Market Study on Microbiome Therapeutics: United States Projected to be the Dominant Regional Market During 2018 – 2025” has been added to the comprehensive repository of Market Research Reports Search Engine (MRRSE) studies the global microbiome therapeutics market in detail, and offers in-depth analysis and insights to readers.
According to the report, the global microbiome therapeutics landscape is likely to reach a valuation of over US$ 897 Mn by 2025. These projections are based on expectations that the various drugs that are in different stages of development will gain regulatory approval. Currently, the market has a presence of over 25 companies, and nearly 25 drugs are in the pipeline for microbiome therapeutics.
According to the study, government support and funding is crucial for the long-term prospects of the microbiome therapeutics market. Governments across the globe, especially in North America and Europe, are taking initiatives to fund the ongoing research and development in the field of microbiome therapeutics. The allocation of US$ 1.6 Bn for microbiome R&D programs is a case in point.
The research study offers market forecast and analysis on the basis of indication and region. The key segments on the basis of indication include type 2 diabetes, primary hyperoxyurea, and obesity. Among these, the C. difficile segment is likely to account for the highest share of the microbiome therapeutics market. The report marks government support as crucial for the long-term prospects of the microbiome therapeutics market.
The report also offers regional analysis and forecast to offer readers in-depth insights on the key areas of growth. According to the research study, North America will continue to be the leading market for microbiome therapeutics globally. The market in North America is likely to be driven by strong government support and increasing emphasis among stakeholders to get regulatory approvals. North America accounts for nearly 50% revenue share of the market.
In addition to North America, Europe is also likely to offer sustained growth opportunities for manufacturers. Many countries in Europe are supporting the research and development in microbiome therapeutics through research and funding activities.
The research report also profiles the business and product strategies of some of the leading players in the microbiome therapeutics market. According to the report, some of the key players in the market include SERES Therapeutics Inc., Synlogic Inc., Rebiotix Inc., Immuron Ltd., 4D Pharma Plc. OxThera AB, Enterome SA, LNC Therapeutics, Microbiome Therapeutics Inc., Ferring B.V., Vedanta Biosciences Inc., Ritter Pharmaceuticals, AOBiome LLC, ViThera Pharmaceuticals Inc., AvidBiotics, Osel Inc. etc.
Browse Full Global Microbiome Therapeutics Market Report with TOC : https://www.mrrse.com/microbiome-therapeutic-market
Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.
MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.
90, State Street
Albany, NY – 12207